All Insights
UK government backs breakthrough tech with £375m future fund
Successor to a coronavirus support scheme as well as a new sovereign investment partnership offer crucial access to capital for
UK passes new law allowing government intervention in transactions on national security grounds
Substantial change is now set for the UK M&A landscape, with a wide range of transactions in scope, including current
Would a global vaccine IP waiver stifle future biopharma breakthroughs?
Pressure for an IP rights waiver to fight the pandemic threatens vaccine companies' ability to develop and protect their trade
Can gene-editing help solve the energy crisis?
What role can biofuels play in fighting climate change and can CRISPR sequencing technology help it reach its potential?
Covid-19: Mitigating the increased risks of corruption in the Life Sciences and Healthcare sector
The pandemic, coupled with the significant economic downturn, continues to produce pressures on businesses that could prove to be fertile
Employee options for fast-growth life sciences and healthcare companies
Attracting, and retaining, talent in today's competitive job market is a key contributor to the success of many businesses. This
Why international arbitration is ideally suited for the Life Sciences and Healthcare sector
Private, flexible and easily enforceable across much of the world, it is not hard to see why international arbitration is
Considerations and best practices for Belgian listed biotech companies when assessing and disclosing inside information (Part 4)
Good practices recommended by the Belgian Financial Services and Markets Authority (FSMA)
Considerations and best practices for Belgian listed biotech companies when assessing and disclosing inside information
What are the best practices for biotech companies in relation to inside information and the Belgian Financial Services and Markets
Considerations and best practices for Belgian listed biotech companies when assessing and disclosing inside information (Part 2)
How does the Belgian Financial Services and Markets Authority (FSMA) determine what qualifies as inside information for biotech companies?
How life sciences companies can strengthen IP strategies through the use of trade secrets
When should trade secrets protection be relied upon and what practical steps can be taken to safeguard valuable confidential information?
Countdown to COP26 | Nature-based solutions and land use
Interest in nature-based solutions has been hotting up since the UK identified it as a campaign issue in the run